<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380573</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20150410H</org_study_id>
    <nct_id>NCT02380573</nct_id>
  </id_info>
  <brief_title>Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease</brief_title>
  <acronym>MB2</acronym>
  <official_title>Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Fox</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Alzheimer’s Research and Care Consortium (TARCC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and
      12-week administration of USP methylene blue (MB) on cerebral blood flow, functional
      connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in
      healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy aging and aging human subjects with mild cognitive impairment and mild Alzheimer's
      disease from the TARCC cohort and South Texas will be studied using a double-blind,
      placebo-controlled design. After informed consent and familiarity with the tasks and the MRI
      environment, the subject will enter an MRI scanner and perform the following 6 tasks.

      fMRI and behavioral data will be collected simultaneously while inside the scanner.

      Delayed match-to-sample task: The subject views a pattern for a few seconds and then is
      prompted to recall the memorized pattern using a response system (approx. 10 mins).

      Face-name task: The subject is shown blocks of stimuli where a novel or familiar face is
      paired with a name. In a later run, the subjects are asked whether the correct name is
      matched with the correct face. (approx. 10 mins).

      Psychomotor vigilance task: The subject receives a visual cue that alerts them to press a
      button as fast as possible. (approx. 10 mins).

      Cerebral Blood Flow and Resting State fMRI: Subject scanned with eyes closed and told to not
      think about a particular topic, each lasting about 10 minutes.

      fMRI data acquisition: fMRI and neuropsychological battery measurements will be made before
      the intervention. These measurements will then be repeated after 2 weeks and 12 weeks.

      fMRI will image changes in regional brain activity associated with these tasks. The MRI pulse
      sequences include diffusion tensor imaging, standard and non-invasive anatomical and
      quantitative MRI for coregistration and blood-oxygen-level dependent (BOLD) fMRI.

      CO2 challenge: Cerebral blood flow measurements will be obtained while the subject rests in
      the scanner after administration of medical-grade 5% CO2 in air for 3-5 minutes. This will be
      repeated on weeks 2 and 12.

      Data analysis: Standard fMRI analysis will be analyzed using established fMRI software.
      Statistical parametric analysis will be performed to generate activation maps. fMRI data will
      be corrected for multiple comparisons using a false discovery rate (q &lt; 0.05) and threshold
      for cluster values to conservatively control for type I error. Behavioral data will be
      analyzed with paired t-test and ANOVA calculations used for group comparison with p &lt; 0.05
      (with Bonferroni correction) considered statistically significant.

      Expected results: The investigators predict that, compared to placebo, MB will: i) improve
      working memory retention in a delayed match-to-sample task by memory performance and enhanced
      fMRI responses in the prefrontal cortex and parietal lobes, ii) improve episodic memory as
      determined by fMRI activation in the hippocampus, medial temporal lobes and prefrontal cortex
      iii) reduce reaction time in a psychomotor vigilance test and enhance fMRI responses within a
      cortical sustained attention network iv) improve CBF and v) improve fMRI connectivity in
      default mode and visuospatial and memory networks/subnetworks. The fMRI and behavioral
      performance effects on memory will be greater in the MCI and mild AD groups than in the
      healthy aging group. The effects will be greater in the MCI and AD groups than in the control
      groups.

      Power analysis: Sample sizes were calculated using an fMRI power tool based on pilot data
      from the current study for a power of 80%, alpha = 0.05, False Discovery Rate &lt; 0.05, to
      detect statistical difference between MB and placebo23. The investigators estimate they will
      need 20-25 subjects per arm of group (complete studies) and thus will recruit 200-240
      subjects to account for potential failed studies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Working memory task fMRI</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>fMRI task blocked activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Working memory task response</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>Working memory task behavioral measures (ie. correct number of responses)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodic memory task fMRI</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>fMRI task blocked activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodic memory task response</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>Face-Name Task behavioral measures (ie. correct recalls)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained attention task fMRI</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>fMRI task blocked activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained attention task reaction time</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>Psychomotor vigilance task (PVT) behavioral measures (ie. reaction time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological battery composite score</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>TARCC designed neurocognitive tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow fMRI measures</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>Resting measurements will be used to assess response and CBF</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Connectivity fMRI measures</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>fMRI measurements will be obtained while the subject rests in the scanner</description>
  </other_outcome>
  <other_outcome>
    <measure>CO2 challenge</measure>
    <time_frame>baseline, change from baseline at 2 weeks ± 3 days, change from baseline at 12 weeks ± 3 days</time_frame>
    <description>Cerebral blood flow measurements will be acquired during a brief (3-5 minutes) inhalation of medical-grade 5% CO2 in air.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>MCI</condition>
  <condition>Aging</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>AD</condition>
  <arm_group>
    <arm_group_label>Healthy Aging MB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Aging Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: FD&amp;C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI) MB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: FD&amp;C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Alzheimer's Disease (AD) MB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Alzheimer's Disease (AD) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: FD&amp;C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Middle Age MB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Middle Age Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: FD&amp;C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <arm_group_label>Healthy Aging MB</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment (MCI) MB</arm_group_label>
    <arm_group_label>Mild Alzheimer's Disease (AD) MB</arm_group_label>
    <arm_group_label>Health Middle Age MB</arm_group_label>
    <other_name>Phenothiazin-5-ium, 3, 7-bis (dimethylamino)-chloride, trihydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FD&amp;C Blue # 2</intervention_name>
    <arm_group_label>Healthy Aging Placebo</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment (MCI) Placebo</arm_group_label>
    <arm_group_label>Mild Alzheimer's Disease (AD) Placebo</arm_group_label>
    <arm_group_label>Health Middle Age Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine hydrochloride</intervention_name>
    <arm_group_label>Healthy Aging MB</arm_group_label>
    <arm_group_label>Healthy Aging Placebo</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment (MCI) MB</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment (MCI) Placebo</arm_group_label>
    <arm_group_label>Mild Alzheimer's Disease (AD) MB</arm_group_label>
    <arm_group_label>Mild Alzheimer's Disease (AD) Placebo</arm_group_label>
    <arm_group_label>Health Middle Age MB</arm_group_label>
    <arm_group_label>Health Middle Age Placebo</arm_group_label>
    <other_name>Azo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all subjects:

          1. 45-89 years old

          2. All genders

          3. All minorities

          4. English, Spanish, or multilingual speakers

          5. Postmenopausal or surgically sterile females only.

          6. Inclusion for MCI group only: participants will meet the criteria for amnestic and
             non-amnestic MCI such as those currently used by Texas Alzheimer's Research and Care
             Consortium (TARCC) consensus diagnosis

          7. Inclusion for AD group only: Alzheimer's Early-stage, sporadic-type

        Exclusion Criteria:

          1. Pregnancy or breastfeeding

          2. Contraindication for MRI (Claustrophobia and magnetic metal implants)

          3. Glucose-6-phosphate deficiency, methemoglobinemia

          4. Allergy to MB

          5. Color-blindness

          6. Craniotomy, craniectomy or endovascular neurosurgery

          7. A current diagnosis of stroke, transient ischemic attack (TIA), any primary
             neurodegenerative disorder, or any other causes of neuropsychologic disturbances or
             secondary dementia (MCI or AD does not exclude subject)

          8. A serious intercurrent illness likely to cause death within the next 5 years, such as
             terminal cancer

          9. Alcohol and/or drug abuse

         10. Any detection of an unknown disease process (eg. new tumor) on the study's
             neuroimaging at the discretion of the investigators

         11. A systolic blood pressure ≥180 mmHg and/or a diastolic blood pressure ≥105 mmHg

         12. Severe difficulty or an inability to perform any one of the 6 Katz Activities of Daily
             Living

         13. Patients who are unlikely to comply with trial visit schedule or with trial
             medication,

         14. On any psychiatric serotonergic antidepressant medication or psychotropic medication
             within the last 5 weeks

         15. Diagnosis of epilepsy, traumatic brain injury with loss of consciousness, psychosis,
             panic attacks,

         16. Chronic kidney disease, cirrhosis, liver or renal transplants

         17. Known hypersensitivity to thiazide diuretics and phenothiazines

         18. Any other condition, which in the opinion of the investigator, would put the
             participant at risk and warrant exclusion from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Imaging Institute, The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.txalzresearch.org</url>
    <description>Texas Alzheimer's Research and Care Consortium</description>
  </link>
  <link>
    <url>http://ric.uthscsa.edu</url>
    <description>Research Imaging Institute</description>
  </link>
  <reference>
    <citation>Bruchey AK, Gonzalez-Lima F. Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. Am J Pharmacol Toxicol. 2008 Jan 1;3(1):72-79.</citation>
    <PMID>20463863</PMID>
  </reference>
  <reference>
    <citation>Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012 Jan;96(1):32-45. doi: 10.1016/j.pneurobio.2011.10.007. Epub 2011 Nov 3. Review.</citation>
    <PMID>22067440</PMID>
  </reference>
  <reference>
    <citation>Telch MJ, Bruchey AK, Rosenfield D, Cobb AR, Smits J, Pahl S, Gonzalez-Lima F. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014 Oct;171(10):1091-8. doi: 10.1176/appi.ajp.2014.13101407.</citation>
    <PMID>25018057</PMID>
  </reference>
  <reference>
    <citation>Lin AL, Poteet E, Du F, Gourav RC, Liu R, Wen Y, Bresnen A, Huang S, Fox PT, Yang SH, Duong TQ. Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS One. 2012;7(10):e46585. doi: 10.1371/journal.pone.0046585. Epub 2012 Oct 9.</citation>
    <PMID>23056355</PMID>
  </reference>
  <reference>
    <citation>Huang S, Du F, Shih YY, Shen Q, Gonzalez-Lima F, Duong TQ. Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. Neuroimage. 2013 May 15;72:237-42. doi: 10.1016/j.neuroimage.2013.01.027. Epub 2013 Jan 26.</citation>
    <PMID>23357077</PMID>
  </reference>
  <reference>
    <citation>Talley Watts L, Long JA, Chemello J, Van Koughnet S, Fernandez A, Huang S, Shen Q, Duong TQ. Methylene blue is neuroprotective against mild traumatic brain injury. J Neurotrauma. 2014 Jun 1;31(11):1063-71. doi: 10.1089/neu.2013.3193. Epub 2014 Apr 8.</citation>
    <PMID>24479842</PMID>
  </reference>
  <reference>
    <citation>Long JA, Watts LT, Chemello J, Huang S, Shen Q, Duong TQ. Multiparametric and longitudinal MRI characterization of mild traumatic brain injury in rats. J Neurotrauma. 2015 Apr 15;32(8):598-607. doi: 10.1089/neu.2014.3563. Epub 2015 Jan 22.</citation>
    <PMID>25203249</PMID>
  </reference>
  <reference>
    <citation>Rodriguez P, Jiang Z, Huang S, Shen Q, Duong TQ. Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. Brain Res. 2014 Nov 7;1588:144-9. doi: 10.1016/j.brainres.2014.09.007. Epub 2014 Sep 8.</citation>
    <PMID>25218555</PMID>
  </reference>
  <reference>
    <citation>Shen Q, Du F, Huang S, Rodriguez P, Watts LT, Duong TQ. Neuroprotective efficacy of methylene blue in ischemic stroke: an MRI study. PLoS One. 2013 Nov 21;8(11):e79833. doi: 10.1371/journal.pone.0079833. eCollection 2013.</citation>
    <PMID>24278191</PMID>
  </reference>
  <reference>
    <citation>Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000 Jun;56(3):247-50.</citation>
    <PMID>10952480</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004 Sep-Oct;11(5):633-40.</citation>
    <PMID>15466319</PMID>
  </reference>
  <reference>
    <citation>Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986 Aug;21(10):915-20.</citation>
    <PMID>3091097</PMID>
  </reference>
  <reference>
    <citation>Mackworth JF. Vigilance, arousal, and habituation. Psychol Rev. 1968 Jul;75(4):308-22. Review.</citation>
    <PMID>4875885</PMID>
  </reference>
  <reference>
    <citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005 Dec;26(4):231-9.</citation>
    <PMID>15954139</PMID>
  </reference>
  <reference>
    <citation>Wang L, Li H, Liang Y, Zhang J, Li X, Shu N, Wang YY, Zhang Z. Amnestic mild cognitive impairment: topological reorganization of the default-mode network. Radiology. 2013 Aug;268(2):501-14. doi: 10.1148/radiol.13121573. Epub 2013 Mar 12.</citation>
    <PMID>23481166</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Peter Fox</investigator_full_name>
    <investigator_title>Professor, Research Imaging Institute Chair</investigator_title>
  </responsible_party>
  <keyword>methylene blue</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

